Moreover, while galunisertib was positively evaluated in some (pre-)clinical studies (39, 40), systemic TGF-β inhibition yielded poor results overall that were attributed in part to cardiovascular toxic side effects and formation of benign tumors (33, 41). This evidence concerns the gene TGFB1 and benign neoplasm.